Europe

The potential cost-effectiveness estimates are significantly higher than what NICE considers to be an appropriate use of NHS resources.

Concerns have risen on potential side-effects of the Anglo-Swedish COVID-19 vaccine.

The shifts in guidance on the Anglo-Swedish drugmaker's vector-based shot demonstrate just how hard it is for policy makers to weigh its benefits against risks in the form of very rare - yet occasionally fatal - cases of blood clotting.

European countries distanced themselves on Friday from a proposal backed by U.S. President Joe Biden to waive patent rights on coronavirus vaccines.

The main challenge to raising production of COVID-19 vaccines is how to quickly and effectively transfer technology, Germany's health minister said Friday, reiterating Berlin's opposition to a U.S. proposal to waive patent protection.

“The main issue for solidarity is the distribution of doses.”

With elections taking place across the UK on 6 May, the Scottish National Party says it plans to take steps to ensure sustainable medicine supply chains and build up the manufacturing of generics and “specials” within the NHS in Scotland.

Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.

The move came after the government late last year issued a compulsory license to a company called Pharmasyntez, which unsuccessfully approached Gilead about obtaining a license to produce a version of the medicine.

UK'S NICE expands utilization of Spinal Muscular Atrophy drug (Spinraza) following a review of data collected as part of the product's Managed Access Agreement (MAA).

Volodymyr Zelensky’s administration has been pressing Washington for help obtaining vaccines since December, before Donald Trump left office.

The EC, which is the executive arm of the European Union, had approved the deal in June 2015, but only on the condition that the companies agreed to sell certain portions of their lab chemicals business.

Watch the virtual launch of NICE's bold and ambitious new 5-year strategy.

The European Union’s contracts for COVID-19 vaccines to be delivered in 2022/23 contain clear rules what would happen if the vaccine makers do not deliver.

The charges revolve around allegations that the companies sold drugs to hospitals at inflated prices as part of a scheme whereby the hospitals then fraudulently obtained funds from the regional government.